The FAERS Public Dashboard and its Value to the Pharmaceutical Industry
Jul 31, 2018 - 00:24:45
Radio and PodcastLive Radio & PodcastsHealth
FDA Requires New Class Warnings for All Gadolinium-Based Contrast Agents
The FDA announced that it is requiring a new class warning and other safety measures for all gadolinium-based contrast agents (GBCAs) for magnetic resonance imaging (or MRI) concerning gadolinium remaining in patients’ b...
About This Episode
FDA Requires New Class Warnings for All Gadolinium-Based Contrast Agents is an episode from FDA Drug Information Updates by ReachMD. The FDA announced that it is requiring a new class warning and other safety measures for all gadolinium-bas...
Podcast
This episode belongs to FDA Drug Information Updates.
Listen Online
Use the player on this page to stream the episode online.
Episode Details
Published Jan 5, 2018, 00:02:59 long, audio available.
Related Episodes
Continue listening to more episodes from FDA Drug Information Updates.
FDA Warns of Serious Immune Reaction with Seizure/BPD Medicine Lamotrigine (Lamictal)
May 4, 2018 - 00:02:59
FDA D.I.S.C.O.: First Biosimilar Approval for the Treatment of Cancer
Jan 7, 2018 - 00:08:29
The FDA's Adverse Event Reporting System (FAERS) Public Dashboard
Oct 29, 2017 - 00:09:22
FDA D.I.S.C.O.: L-Glutamine for Sickle Cell Disease
Aug 17, 2017 - 00:05:29
FDA D.I.S.C.O.: Osimertinib for Non-Small Cell Lung Cancer
Jul 28, 2017 - 00:06:00
FDA D.I.S.C.O.: Two Approvals for ALK-Positive Non-Small Cell Lung Cancer
Jul 25, 2017 - 00:09:00